Correction for Lawes et al., Stroke 35 (3) 776-785.

This Article Full Text Full Text (PDF) All Versions of this Article: 35/4/1024    most recent 01.STR.0000126208.14181.DDv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lawes, C. M.M. Articles by Rodgers, A. Search for Related Content PubMed Articles by Lawes, C. M.M. Articles by Rodgers, A.

(Stroke. 2004;35:1024.)
© 2004 American Heart Association, Inc.

Blood Pressure and Stroke

An Overview of Published Reviews

Carlene M.M. Lawes, MBChB, FAFPHM, PhD; Derrick A. Bennett, MSc, PhD, CStat; Valery L. Feigin, MD, MSc, PhD Anthony Rodgers, MBChB, FAFPHM, PhD

From the Clinical Trials Research Unit, Department of Medicine, University of Auckland, Auckland, New Zealand.

Correspondence to Carlene Lawes, Clinical Trials Research Unit, Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand. E-mail c.lawes{at}ctru.auckland.ac.nz

Abstract

Background— The last few years have seen a considerable increase in the amount of information available concerning blood pressure (BP) and stroke associations. This article provides an overview of published reviews of the effects on stroke seen in trials of BP-lowering drugs and compares these with the results available from cohort studies.

Summary of Review— We present a review of major overviews of prospective cohort studies and an updated meta-analysis of >40 randomized controlled trials of BP lowering, which included >188 000 participants and approximately 6800 stroke events. Cohort studies now indicate that in the Asia Pacific region as well as in North America and Western Europe, each 10 mm Hg lower systolic BP is associated with a decrease in risk of stroke of approximately one third in subjects aged 60 to 79 years. The association is continuous down to levels of at least 115/75 mm Hg and is consistent across sexes, regions, and stroke subtypes and for fatal and nonfatal events. The proportional association is age dependent but is still strong and positive in those aged 80 years. Data from randomized controlled trials, in which mean age at event was approximately 70 years, indicate that a 10 mm Hg reduction in systolic BP is associated with a reduction in risk of stroke of approximately one third. Per mm Hg systolic BP reduction, the relative benefits for stroke appear similar between agents, by baseline BP levels, and whether or not individuals have a past history of cardiovascular disease. There is, however, evidence of greater benefit with a larger BP reduction.

Conclusions— The epidemiologically expected benefits of BP lowering for stroke risk reduction are broadly consistent across a range of different population subgroups. There are greater benefits from larger BP reductions, and initiating and maintaining BP reduction for stroke prevention is a more important issue than choice of initial agent.

Key Words: blood pressure • cohort studies • epidemiology • meta-analysis • randomized controlled trials • stroke

This article has been cited by other articles:

				V. Aiyagari and P. B. Gorelick Management of Blood Pressure for Acute and Recurrent Stroke Stroke, June 1, 2009; 40(6): 2251 - 2256. [Full Text] [PDF]

				G. J. Hankey Response to Letter by Castilla-Guerra et al Stroke, March 1, 2009; 40(3): e76 - e76. [Full Text] [PDF]

				S. Inaba, M. Iwai, Y. Tomono, I. Senba, M. Furuno, H. Kanno, H. Okayama, M. Mogi, J. Higaki, and M. Horiuchi Exaggeration of Focal Cerebral Ischemia in Transgenic Mice Carrying Human Renin and Human Angiotensinogen Genes Stroke, February 1, 2009; 40(2): 597 - 603. [Abstract] [Full Text] [PDF]

				H. P. Adams Jr Secondary Prevention of Atherothrombotic Events After Ischemic Stroke Mayo Clin. Proc., January 1, 2009; 84(1): 43 - 51. [Abstract] [Full Text] [PDF]